AMO Pharma Limited (AMO Pharma) today announced initiation of a phase 2 clinical study in the U.K. for AMO-02 (tideglusib).
MDF and the Wyck Foundation have awarded new grants to develop phenotypic mouse models of DM as well as new DM1 and DM2 cell lines. Read more about these new partnerships.
A new study from Dr. Dimitri Renard and his team applies metabolic imaging to identify brain regions affected in DM1. Read about their findings here.
We are the focus of the latest “BioFlash" podcast by the San Francisco Business Times! Check out the interviews with our incredible champions, Erica and Jeremy Kelly (Chairman of the MDF Board), and our CEO, Molly White. We are thrilled by this opportunity to raise awareness of DM in the biotech community. Click here to read the article and listen to the podcast.
MDF and the Wyck Foundation jointly announce the funding of two new research projects. The projects address critical gaps in research infrastructure and clinical trial readiness and will increase understanding of the progression of DM, and provide measures to evaluate disease progression and the efficacy of candidate therapeutics.